FP7 Health partner search for tuberculosis drug development
American SME Sequella Inc. is looking for partners for preclinical and early clinical development of new drug candidates for the treatment of multidrug-resistant tuberculosis (MDR-TB) under FP7 (or even Eurostars).
Sequella Inc. is a private, clinical-stage pharmaceutical company that addresses the challenge of antibiotic-resistant bacterial diseases by discovery, development, and commercialization of first-inclass antibiotics with novel mechanisms of action.
The company is looking for an SME and at least two other European partners in different member states/associated countries to develop a consortium to submit a proposal for the FP7 Health 2013 call area 2.3.1 Anti-microbial drug resistance. The SME would be the primary applicant.
The aim of the project is to support preclinical and early
clinical development of two promising new drug candidates
(SQ609 and SQ641) for the
treatment of MDR-TB. The proposed research should include:
1.)
small molecule manufacturing development
2.) preclinical
pharmacokinetics, safety, and technology studies
3.) Phase
1 and Phase 2 studies of the drug candidates
Existing partners/expertise:
Sequella has significant expertise in discovery, research
and development, and preclinical and clinical drug development
for infectious diseases. We successfully discovered and
developed a drug candidate for TB that is currently in Phase 2b
clinical trials. Because we are a U.S. small business, we cannot
participate directly in this call. However, we would
contribute our expertise about the molecule and be involved in
manufacturing, preclinical development studies, and clinical
studies.
Current stage of development:
Proof-of-principle in animal model efficacy studies. This
drug candidate has very promising activity in mouse models of
TB. The manufacturing process is established and much of the
necessary absorption, distribution, excretion, and metabolism
(ADME) studies have been completed.
Interested persons should contact Katherine Sacksteder at [email protected].
Further information on Sequella Inc. and the drugs SQ609 and SQ641
Euresearch
http://www.euresearch.ch/index.php?id=395&tx_ttnews[tt_news]=3518&cHash=0ebfdce47b
